DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Staccato Loxapine Pulmonary Safety in Patients With Asthma

Information source: Alexza Pharmaceuticals, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Intervention: Staccato Loxapine (Drug); Staccato Placebo (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Alexza Pharmaceuticals, Inc.

Official(s) and/or principal investigator(s):
Mildred D. Gottwald, PharmD, Study Director, Affiliation: Alexza Pharmaceuticals, Inc.

Summary

The purpose of this study is to assess the safety of 2 inhaled doses of Staccato Loxapine within a day in patients with asthma.

Clinical Details

Official title: Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Asthma

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Change in FEV1 from baseline by spirometry

Secondary outcome:

Change in FVC from baseline by spirometry

Treatment emergent adverse events

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- History of mild to moderate persistent asthma for at least 6 months with

pre-bronchodilator FEV1 ≥60% of predicted value. Exclusion Criteria:

- History of COPD, or any other acute or chronic pulmonary disease

Locations and Contacts

Allergy and Asthma Medical Group & Research Center, A.P.C., San Diego, California 92123, United States
Additional Information

Starting date: May 2009
Last updated: August 28, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017